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One aspect of concern for survivors of Wilms’ tumour has been the late outcome in terms of renal function. Previous studies
have documented low glomerular ﬁltration rate and high blood pressure in some patients. Furthermore, disorders in tubular
function (especially urinary concentration defects) have been suggested but not conﬁrmed in small studies. The aim of this
study was to determine the prevalence and nature of subclinical and overt glomerular, proximal and distal renal tubular
toxicity in a population based cohort of survivors of Wilms’ tumour. Forty patients (24 female) with a median age of 4.3 years
(3 months–11.8 years) at diagnosis were studied. Median follow-up was 8.8 (range 0.06–27.5) years. Glomerular ﬁltration
rate was measured by
51Cr-EDTA plasma clearance, proximal tubular function by electrolyte fractional excretions, urine
excretion of low molecular weight proteins (retinol-binding protein) and renal tubular enzymes (alanine aminopeptidase; N-
acetylglucosaminidase) and distal tubular function by the osmolality of the ﬁrst two urines of the day on 3 consecutive days.
Renal size (ultrasound) and blood pressure were also measured. Mean (range) glomerular ﬁltration rate was 100 (61–150)
ml min
71 1.73 m
72. Nine were below the reference range for healthy individuals with two kidneys. Most serum electrolyte
concentrations (sodium, potassium, chloride, calcium, magnesium and phosphate) fell within the normal range for age, as did
the fractional excretions. The values that fell outside the normal range were only marginally abnormal. Subclinical measures of
tubular toxicity (retinal-binding protein, alanine aminopeptidase, N-acetylglucosaminidase) were abnormal in only four patients.
Thirty-seven patients achieved maximal urine osmolalities 5800 mOsm kg
71, but three failed to achieve this value even after
DDAVP administration. Two patients had evidence of increased urinary albumin excretion. Compensatory renal hypertrophy
was seen in all but two patients, but blood pressure was within normal limits in all patients. Current and past treatment for
Wilms’ tumour does not have any clinically important nephrotoxic effect in the majority of patients. This ﬁnding will enable
paediatric oncologists to reassure patients and parents that treatment for Wilms’ tumour rarely causes long-term renal
impairment.
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Nephroblastoma or Wilms’ tumour is one of the commonest solid
malignancies in childhood, with an incidence of one in 10000 live
births (Mitchell, 1997). This triphasic tumour occurs usually
between the ages of 2 and 7 years (Breslow and Beckwith, 1982)
with an equal sex incidence. Nephrectomy was ﬁrst described as
treatment for this tumour in the 1940s (Priestly and Shulte,
1942) and since that time the adjuvant treatment has undergone
a number of changes. Radiotherapy and chemotherapy have been
used, often in combination. Chemotherapy has been used both
pre- and post-nephrectomy. Advances in therapy have resulted in
a greatly improved survival rate for all stages of the disease. In
1910 virtually all children with Wilms’ tumour died; by 1950 with
the advent of safe anaesthesia and radiotherapy survival had risen
to 50%, and current treatment leads to survival in excess of 90%
(Mitchell, 1997).
With this excellent prognosis there has been a shift towards
attempts to reduce the late toxicity of treatment of these children
without compromising their prognosis. One such area of concern
has been functional impairment of the remaining kidney. Reduc-
tion of the duration or intensity of chemotherapy and
radiotherapy occurred in successive studies over the last 30 years.
Nephron sparing surgery rather than total nephrectomy to reduce
the impact of possible late effects on a solitary kidney has been
suggested.
There is still relatively little data on the function of the remain-
ing kidney after treatment for Wilms’ tumour. Reported effects
after treatment for Wilms’ tumour have included reduction in
glomerular ﬁltration rate (GFR) (Walker et al, 1982; Robitalle et
al, 1985; Levitt et al, 1992), microalbuminuria (Levitt et al, 1992;
di Tullio et al, 1996) (rarely resulting in hyperﬁltration induced
glomerulosclerosis and subsequent renal failure), failure of
compensatory hypertrophy of the remaining kidney (Wikstad et
al, 1986; Makipernaa et al, 1991; Levitt et al, 1992) and hyperten-
sion (Levitt et al, 1992).
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nature of renal toxicity in survivors of children treated for Wilms’
tumour.
PATIENTS AND METHODS
Patients
Fifty-eight survivors of children who presented with Wilms’
tumour between 1966 and 1998 in the North of England were
identiﬁed from the North of England Young Persons Malignant
Disease Registry. Forty patients were studied (69%); of the remain-
ing 18 patients 13 had moved from the area, three declined the
invitation to participate, and their general practitioners suggested
that it was inappropriate to approach two patients.
Out of the forty patients studied 24 were female (60%). The
median age at diagnosis was 4.3 (years) (3 months–11.8 years).
The median duration of follow up was 8.8 years (range 0.06–
27.5). The right kidney was affected in 24 patients (61.5%). Eigh-
teen patients (45%) had stage I disease, nine (22.5%) stage II
disease, seven (17.5%) stage III disease, ﬁve (12.5%) stage IV
disease and one (2.5 %) stage V disease. Out of the 18 patients
not studied seven (39%) had stage I disease, four (22%) stage II
disease, six (33%) stage III disease and one (5.5%) had stage IV
disease. The median age at diagnosis of these patients was 3.0 years
(range 0.05–7.2). Two of these patients were diagnosed during the
1960’s, nine during the 1970’s, four during the 1980’s and two
during the 1990’s. Out of the eight patients not studied and treated
before the mid 1970’s ﬁve had whole abdominal radiotherapy.
Treatment
Children were treated with a combination of surgery (all patients),
radiotherapy (19 patients – 47.5%) and chemotherapy (all
patients) (Table 1). Surgery involved unilateral nephrectomy in
all but one patient with stage 5 disease who had a wedge resection
of one kidney and a complete removal of the other. Radiotherapy
varied during the time period covered by the study. In the earlier
years (prior to 1974) randomisation between whole abdominal
radiotherapy and ﬂank radiotherapy was performed but after this
date ﬂank radiotherapy was used in most patients. Out of the 19
patients receiving radiotherapy, ﬁve had whole abdominal radio-
therapy, and 14 had ﬂank radiotherapy (median dose of 3.3 Gy
to remaining kidney). The median dose to the kidney bed (i.e.
on tumour side) was 30 (range 19.8–34) Gy given in a median
of 16 fractions (range 10–22). Three patients also had radiother-
apy to their lungs as well as their abdomens. Chemotherapy was
given to all patients, four had actinomycin alone (10%), 16 had
vincristine alone (40%), eight had vincristine and actinomycin
(20%), 11 had vincristine, actinomycin and doxorubicin (27.5%)
and one patient had vincristine, actinomycin, doxorubicin and
cyclophosphamide (2.5%). Most patients were treated according
to national protocols, i.e. MRC 1 from 1970–1974, MRC 2 from
1974–1980, UKCCSG Wilms 1 from 1980–1986, UKCCSG Wilms
2 from 1986–1991 and UKCCSG Wilms 3 from 1991 onwards.
Renal investigations
Glomerular ﬁltration rate was measured by
51Cr-EDTA plasma
clearance.
Proximal tubular function was evaluated by plasma electrolyte
concentrations and fractional excretions (sodium, potassium,
chloride, magnesium, phosphate, calcium and glucose). Fractional
excretion was calculated by the formula: (urine electrolyte concen-
tration/serum electrolyte concentration)6(serum creatinine
concentration/ urine creatinine concentration)6100. An increased
fractional excretion is only signiﬁcant if the corresponding serum
electrolyte concentration is reduced. The Tmp/GFR is a measure
of the renal tubular threshold for phosphate and is deﬁned as
plasma phosphate–(urine phosphate6plasma creatinine)/urine
creatinine.
Sub-clinical measures of renal tubular impairment were
measured by urine concentrations of a low molecular weight
protein (retinol-binding protein, RBP) and of two renal tubular
enzymes (alanine aminopeptidase, AAP and N-acetylglucosamini-
dase, NAG).
Distal tubular function was evaluated by the osmolality of the
ﬁrst two urines of the day on 3 consecutive days. If a maximal
urine concentration of 800 mOsm kg
71 was not achieved then
DDAVP was administered and the subsequent maximal urine
concentration recorded. Fasting serum arginine-vasopressin levels
were also measured.
Urinary albumin excretion was determined using an untimed
urine sample and applying the formula urine albumin (mg)/urine
creatinine (mmol).
Renal size (measured by ultrasound) was evaluated using
the formula: length6width6(longitudinal+transverse depth)/
260.523 (Wikstad et al, 1986).
Blood pressure (BP) was measured using a mercury sphygmo-
manometer. The current BP of patients not studied was obtained
in 14 out of 18 patients by contacting their general practitioners.
Ethical Approval was obtained from the Newcastle and North
Tyneside Health Authority (Min. ref. 94/282).
RESULTS
Glomerular
Glomerular ﬁltration rate was measured in all 40 patients with a
median of 100 ml min
71 1.73 m
72 (range 61–150). Nine patients
had a GFR below the reference range for healthy individuals with
two kidneys (490 ml min
71 1.73 m
72), and four had a GFR
below 80 ml min
71 1.73 m
72 (Figure 1 and Table 1). There
appeared to be a weak but signiﬁcant correlation between renal
volume and GFR in the study patients (r=0.37, P=0.03) (Figure
2). Those patients with larger renal volumes tended to have higher
GFR. This may suggest a degree of hyperﬁltration of the remaining
kidney. There was no signiﬁcant difference in the GFR of those
patients who had received radiotherapy compared to those that
did not (P=0.2, Mann–Whitney U-test).
Proximal tubular function
Serum electrolyte concentrations are shown in Table 2 and their
fractional excretions in Table 3. All those values that fell outside
the normal range were only marginally abnormal. Those with frac-
tional excretions outside the reference ranges all had normal serum
electrolyte concentrations. Out of the eight serum magnesium
concentrations that fell outside the reference range, seven were only
marginally low but the other was moderately elevated; in the case
of four abnormal serum phosphate concentrations, three were
marginally lower and one higher than the reference range. Out
of the seven patients with marginally decreased serum magnesiums,
four also had marginally decreased Tmp/GFR’s and two of the eight
also had marginally decreased serum phosphates. Five of the seven
patients with decreased magnesium concentrations received radio-
therapy during their treatment. None of these patients had
abnormal urinary enzyme excretion.
Sub-clinical proximal tubular toxicity
The median urine RBP concentration was 5.95 mg mmol
71 Cr
(range 0.45–63), three values were outside the normal range.
The median urine AAP concentration was 1 U mmol
71 Cr
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The median urine NAG concentration was 0.2 U mmol
71 Cr
(range 0.07–0.5), four values were outside the normal range
(Figure 3).
Distal tubular function
Maximal urine concentrations of more than 800 mOsm kg
71 were
achieved in 37 patients with a median value of 859 mOsm kg
71
and a range of 182–1251 mOsm kg
71. In three patients the maxi-
mal concentration did not reach 800 mOsm kg
71 despite DDAVP
administration. These three patients had maximal concentrating
ability of 520, 640 and 560 mOsm kg
71 despite the administration
of DDAVP. The GFR in these patients were 109, 109,
100 ml min
71 1.73 m
72 respectively.
Serum vasopressin concentrations were measured in 31 patients
and ranged between 0.4 and 9.8 pg ml
71 (median=1.8 pg ml
71),
four fell marginally outside the normal reference range (three lower
and one higher) corrected for plasma osmolality.
Urine albumin excretion
Urine albumin/creatinine ratio was measured in 36 patients and
ranged from 0.02–46.7 mg mmol
71 (median 1.43) (normal
range=510 mg mmol
71). Increased albumin excretion was found
in two patients (5%). These patients had no other abnormality in
renal function.
Blood pressure
Systolic BP ranged between 80 and 120 mmHg (median
108 mmHg). The z-scores related to the medians for age (Task
Force, 1987) ranged between –1.51 and 1.80 (median –0.24)
(Figure 4). Diastolic BP ranged between 46 and 80 mmHg (median
70 mmHg). The z-scores ranged between –1.57 and 1.27 for age
(median 0.23). There were no abnormal systolic or diastolic blood
pressures in the patients studied (Table 1). The systolic BP for 14
patients unable to take part in the study ranged between 100 and
140 mmHg (median 120 mmHg) and the diastolic between 60 and
90 mmHg (median 76 mmHg). One of these 14 individuals was
being treated for hypertension and four out of 14 had systolic
BPs over 130 mmHg but less than 140 mmHg. These tended to
be patients who were treated in the early part of the study period.
We were unable to obtain information about the BP of four
patients.
Renal size
Renal size of 38 patients was recorded using the method
described by Dinkel (1985). Renal volume ranged from
77.3–510 ml (median=173 ml) (Table 1). Compensatory hyper-
trophy (kidney length greater than two standard deviations
above the mean for age and weight) was seen in 36 patients,
the other two patients had renal sizes above the median for
their weight.
Inﬂuence of age
Four patients were less than 1 year old and 10 were less than 2
years old at diagnosis; their results did not differ signiﬁcantly from
the rest of the patients studied.
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Abnormalities in renal function were too infrequent to evaluate the
relevance of different components of treatment in the development
of renal impairment (Table 1).
DISCUSSION
With the survival of children for Wilms’ tumour being about 90%
for all stages combined the emphasis of treatment for this condi-
tion has shifted to minimise the toxicity of treatment while not
compromising efﬁcacy. Damage to the surviving kidney is a poten-
tial concern among those treating children with Wilms’ tumour
and it is important to fully document this effect and determine
its signiﬁcance in clinical practice.
There have been a number of studies with varying results look-
ing at BP in survivors of Wilms’ tumours (Table 4), the largest of
these being the NWTS study in which 7% of patients had an
increased systolic BP after 5 years and the same number had an
increase in diastolic BP (Kantor et al, 1989). Several studies showed
no increase in blood pressure and others varied from 1–25%.
However, the numbers of most studies are small.
Glomerular ﬁltration rate has been measured in various series
after treatment for Wilms’ tumour, all of which show a small
number of children with a low GFR (Table 5). The normal values
that have been used in most cases are those for children with two
kidneys. The median GFR is marginally higher than that described
in other studies for nephrectomised patients with both malignant
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Table 2 Electrolyte measurements in patients with Wilms’ tumour
Number of
Number of Median Range Normal range patients outside
Electrolyte patients (mmol l
71) (mmol l
71) (mmol l
71) normal range
Sodium 40 140 135–146 135–145 1 (4)
Potassium 40 4.25 3.7–5.4 3.5–5.0 2 (24)
Chloride 40 103.5 98–110 96–109 1 (4)
Creatinine 40 70 48–116 35–110 (mmol l
71)2 ( 2 4)
Magnesium 38 0.74 0.63–1.22 0.7–1.0 8 (14,7 5)
Phosphate 39 1.3 0.81–2.37 0.9–2.25 4 (45)
Calcium (ionised) 37 1.24 1.22–1.33 1.19–1.37 0
Glucose 38 5.1 4.0–8.3 3.3–7.4 2 (24)
Osmolality 38 289 277–304 270–298 (mOsm kg
71)2 ( 2 4)
Table 3 Electrolyte fractional excretions in patients with Wilms’ tumour
Fractional Number of Median Range Normal
excretion patients (%) (%) range (%)
Sodium (FNa) 39 0.64 0.03–1.8 0.16–1.93
Potassium 38 15.6 0.99–32.7 3.52–30.6
Chloride 34 1.38 0.01–3.63 0.32–2.51
Magnesium 37 3.60 0.58–8.33 1.13–9.13
Phosphate (TM
p/GFR) 39 1.30 0.8–2.35 41.0 mmol l
71
Calcium 23 1.03 0.04–3.15 0.11–5.64
Glucose 28 0.02 0.001–0.05 0.00–0.05
No patient had an abnormal fractional excretion in the presence of abnormal serum
electrolytes.
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Figure 3 Urinary excretion of RBP, NAG and AAP. The median urine
RBP concentration was 5.95 mg mmol
71 Cr (range 0.45–63). The median
urine AAP concentration was 1 U mmol
71 Cr (range 0.32–2). The med-
ian urine NAG concentration was 0.2 U mmol
71 Cr (range 0.07–0.5).
The solid horizontal lines represent the upper limit of the reference range.
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Figure 4 Frequency histogram of systolic blood pressure. The z-scores
related to the medians for age ranged between 71.51 and 1.8 (median
70.24).
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71 1.73m
72) (Walker et
al, 1982; Robitalle et al, 1985). The reduction in GFR after treat-
ment does not appear to be a major clinical problem. It has
been suggested (de Graaf et al, 1996) the GFR is reduced in those
children who have received radiotherapy compared to those who
had chemotherapy alone. However this was not the case in this
study. A reason for this may be the longer follow up period in this
study (median 158 months vs 13 months). The median GFR in this
study was higher than expected with a number of patients with
values in excess of 110 ml min
71 1.73m
72. Although renal plasma
ﬂow with and without protein loading were not performed the
suggestion of hyperﬁltration may be made on the basis of GFR
alone (Donckerwolke and Coppes, 2001). Although no signiﬁcant
renal damage was noted in these patients at the present time this
may in fact develop in the future with a longer period of follow-
up.
A number of studies have been reported with regard to various
aspects of proximal tubular function and proteinuria in survivors
of Wilms’ tumour (Table 6). The vast majority of studies have
not comprehensively studied the range of possible complications
relating to the proximal tubule. While the results vary, there
appears to be some degree of proteinuria (usually microalbuminur-
ia) in a signiﬁcant minority of patients, although this does not
seem to cause clinical problems. Although there was some overlap
of electrolyte abnormalities in individual patients none of these
patients had more than two minor abnormalities. Proximal tubular
abnormalities would be unexpected in children having had treat-
ment for Wilms’ tumour as the chemotherapy does not involve
drugs which are known to have a major effect on proximal tubular
function.
Distal tubular function has rarely been studied (Table 6). While
some abnormalities were detected these appear to be of little clin-
ical relevance to the patients. Impaired compensatory hypertrophy
in the remaining kidney has been found in half the patients in one
study but not in two others (Table 7).
The limited number of previous studies has indicated that
hypertension occurs in 7% (Finkelstein et al, 1993) of children
treated for Wilms’ tumour although in a study of 119 survivors
Kantor found no hypertensive patients (Kantor et al, 1989). The
results of our study are consistent with this ﬁnding that hyperten-
sion in survivors of Wilms’ tumour is not a common clinical
problem. Compensatory renal hypertrophy was found in all but
two of our patients. These two patients did not have any other
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Author Raised BP Number of patients
Jereb et al, 1973 none 16
Robitaille et al, 1985 none 27, 4 with Wilms’
Wikstad et al, 1986 none 22
Kantor et al, 1989 none 118
Sanchez de Toledo et al, 1989 10% 40
Landman Parker et al, 1991 6% 86
Makiperna et al, 1991 17% 30
Levitt et al, 1992 11% 53
Janda et al, 1993 20% 20
Finkelstein et al, 1993 4% 1528
7% after 5 years 1171
Di Tullio et al, 1996 none 34
Bailey (this study) 2% 54
Table 5 GFR measurements in survivors of Wilms’ tumours
Number with decreased GFR
(in comparison to normal)
values for two kidney
Author individuals) Number in study
Wikstad et al, 1986 82% 22
Sanchez de Toledo et al, 1989 7.5% 40
Buyukpamukcu et al, 1989 13.5% 37
Blake and Gerrard, 1991 40% 25
Landman Parker et al, 1991 4.3% 116
Makiperna et al, 1991 none 30
Levitt et al, 1992 19% 53
Jereb et al, 1993 none 20
Janda et al, 1993 5% 20
De Graaf et al, 1996 17% 41
Bailey (this study) 22% 40
Table 6 Tubular abnormalities in survivors of Wilms’ tumour
Proximal tubular Distal tubular
Author dysfunction Patients Proteinuria Patients dysfunction Patients
Jereb et al, 1973 Decreased Na excretion 6/8 Subclinical impairment in 73% 11
Robitaille et al, 1985 nil 4
Sanchez de Toledo et al, 1989 nil 40 none 40
Makiperna et al, 1991 nil 30
Buyukpamukcu et al, 1989 57% 37
Landman Parker et al, 1991 4% 116
Levitt et al, 1992 9% (m’albuminuria) 53
Di Tullio et al, 1996 12% (32% m’albuminuria) 34
Janda et al, 1993 5% (35% m’albuminuria) 20 Decrease in urine osmolality in 50% 20
Blake and Gerrard, 1991 33% (m’albuminuria) 18 Urine concentration 5600 mosm kg
71 25
in two patients
Bailey (this study) nil 40 5% (m’albuminuria) 36 Urine concentration 5800 mosm kg
71 40
in three patients
M’albuminuria=microalbuminuria.
Table 7 Compensatory renal hypertrophy in survivors of Wilms’ tumour
Number of
Author Dysfunction patients
Makiperna et al, 1991 Poor growth in 13% 30
Levitt et al, 1992 Poor growth in 45% 53
Di Tullio et al, 1996 Poor growth in 3% 34
Bailey (this study) Hypertrophy 52 s.d. above 38
mean in 5% of patients
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diagnosis (Levitt et al, 1992) and their treatment was not different
from other patients. The results of our study that lack of compen-
satory hypertrophy is not a signiﬁcant problem in survivors of
Wilms’ tumour is in contrast to suggestions by others (Green
and Jaffe, 1979; Zuchelli et al, 1983). The type of treatment, includ-
ing whether or not radiotherapy was given, did not appear to
inﬂuence renal dysfunction; this is in keeping with previous studies
(Jereb et al, 1973; Luttenegger et al, 1975; Walker et al, 1982). The
type of radiotherapy (whole abdomen vs ﬂank) did not appear to
exert an inﬂuence on toxicity.
Although there was some evidence of minor renal dysfunction in
some of our patients, these abnormalities appeared to be isolated.
Three patients had evidence of minor impairment of renal concen-
trating ability but not of a degree sufﬁcient to cause clinical
problems. Nine patients had a marginally reduced GFR but again
the magnitude of these abnormalities was small and unlikely to
cause clinical sequelae. There was no evidence of clinically relevant
proximal renal dysfunction in any patient. Proximal tubular func-
tion of survivors of Wilms’ tumours has not been evaluated in this
degree of detail before, so direct comparison is not possible.
Hyperﬁltration and subsequent development of focal glomerulo-
sclerosis and renal failure is a concern of many paediatric
oncologists treating Wilms’ tumour. Increased excretion of albu-
min has been described in up to a third of patients surviving
Wilms’ tumour (Levitt et al, 1992; di Tullio et al, 1996) but was
rare in our patients. Although the two patients with microalbumi-
nuria may develop late glomerular problems, none are yet apparent
5 and 6 years after treatment. The signiﬁcance of the increase in
GFR in some of our patients is unknown but may lead to hyperﬁl-
tration injury and resultant renal damage in the future.
Although the 18 patients not studied were mainly from the early
part of the study period, this may have led to some bias of the
results. The age at diagnosis and the stage however were similar
to that of the population studied.
In conclusion, we have shown in a population-based study that
there is no clinically signiﬁcant toxicity associated with either past
or present treatment for this condition. This should help paediatric
oncologists to reassure patients and parents that treatment for
Wilms’ tumour is unlikely to cause long-term renal impairment
and reassure paediatric surgeons that nephron sparing surgery is
not necessarily important in these children.
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